Colon Cancer - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 434 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Colon Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Colon Cancer - Pipeline Review, H2 2014', provides an overview of the Colon Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colon Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Colon Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Colon Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Colon Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
Introduction 7
Colon Cancer Overview 8
Therapeutics Development 9
Colon Cancer - Therapeutics under Development by Companies 11
Colon Cancer - Therapeutics under Investigation by Universities/Institutes 19
Colon Cancer - Pipeline Products Glance 22
Colon Cancer - Products under Development by Companies 26
Colon Cancer - Products under Investigation by Universities/Institutes 35
Colon Cancer - Companies Involved in Therapeutics Development 38
Colon Cancer - Therapeutics Assessment 123
Drug Profiles 137
Colon Cancer - Recent Pipeline Updates 355
Colon Cancer - Dormant Projects 402
Colon Cancer - Discontinued Products 406
Colon Cancer - Product Development Milestones 407
Appendix 415

List of Tables
Number of Products under Development for Colon Cancer, H2 2014 27
Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2014 28
Number of Products under Development by Companies, H2 2014 30
Number of Products under Development by Companies, H2 2014 (Contd..1) 31
Number of Products under Development by Companies, H2 2014 (Contd..2) 32
Number of Products under Development by Companies, H2 2014 (Contd..3) 33
Number of Products under Development by Companies, H2 2014 (Contd..4) 34
Number of Products under Development by Companies, H2 2014 (Contd..5) 35
Number of Products under Development by Companies, H2 2014 (Contd..6) 36
Number of Products under Investigation by Universities/Institutes, H2 2014 38
Comparative Analysis by Late Stage Development, H2 2014 40
Comparative Analysis by Clinical Stage Development, H2 2014 41
Comparative Analysis by Early Stage Development, H2 2014 42
Comparative Analysis by Unknown Stage Development, H2 2014 43
Products under Development by Companies, H2 2014 44
Products under Development by Companies, H2 2014 (Contd..1) 45
Products under Development by Companies, H2 2014 (Contd..2) 46
Products under Development by Companies, H2 2014 (Contd..3) 47
Products under Development by Companies, H2 2014 (Contd..4) 48
Products under Development by Companies, H2 2014 (Contd..5) 49
Products under Development by Companies, H2 2014 (Contd..6) 50
Products under Development by Companies, H2 2014 (Contd..7) 51
Products under Development by Companies, H2 2014 (Contd..8) 52
Products under Investigation by Universities/Institutes, H2 2014 53
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 54
Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 55
Colon Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 56
Colon Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2014 57
Colon Cancer - Pipeline by AlphaVax, Inc., H2 2014 58
Colon Cancer - Pipeline by Ambrx, Inc., H2 2014 59
Colon Cancer - Pipeline by Anavex Life Sciences Corp., H2 2014 60
Colon Cancer - Pipeline by Aphios Corporation, H2 2014 61
Colon Cancer - Pipeline by Apogenix GmbH, H2 2014 62
Colon Cancer - Pipeline by Aptose Biosciences Inc., H2 2014 63
Colon Cancer - Pipeline by AstraZeneca PLC, H2 2014 64
Colon Cancer - Pipeline by Aurigene Discovery Technologies Limited, H2 2014 65
Colon Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2014 66
Colon Cancer - Pipeline by Biokine Therapeutics Ltd., H2 2014 67
Colon Cancer - Pipeline by Bionomics Limited, H2 2014 68
Colon Cancer - Pipeline by Cellceutix Corporation, H2 2014 69
Colon Cancer - Pipeline by Cold Genesys, Inc., H2 2014 70
Colon Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 71
Colon Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H2 2014 72
Colon Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2014 73
Colon Cancer - Pipeline by CZ BioMed Corp, H2 2014 74
Colon Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 75
Colon Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 76
Colon Cancer - Pipeline by DEKK-TEC, Inc., H2 2014 77
Colon Cancer - Pipeline by Dendreon Corporation, H2 2014 78
Colon Cancer - Pipeline by Digna Biotech, S.L., H2 2014 79
Colon Cancer - Pipeline by EntreChem, S.L., H2 2014 80
Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 81
Colon Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 82
Colon Cancer - Pipeline by GlycaNova Norway AS, H2 2014 83
Colon Cancer - Pipeline by Green Cross Corporation, H2 2014 84
Colon Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 85
Colon Cancer - Pipeline by Histogen, Inc., H2 2014 86
Colon Cancer - Pipeline by Igenica Biotherapeutics, Inc., H2 2014 87
Colon Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2014 88
Colon Cancer - Pipeline by Immunomedics, Inc., H2 2014 89
Colon Cancer - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2014 90
Colon Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2014 91
Colon Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H2 2014 92
Colon Cancer - Pipeline by JW Pharmaceutical Corporation, H2 2014 93
Colon Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 94
Colon Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 95
Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2014 96
Colon Cancer - Pipeline by Longevity Biotech, Inc, H2 2014 97
Colon Cancer - Pipeline by Mabion SA, H2 2014 98
Colon Cancer - Pipeline by Merus B.V., H2 2014 99
Colon Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 100
Colon Cancer - Pipeline by Molecular Targeting Technologies, Inc., H2 2014 101
Colon Cancer - Pipeline by MolMed S.p.A., H2 2014 102
Colon Cancer - Pipeline by Multimmune GmbH, H2 2014 103
Colon Cancer - Pipeline by Nanobiotix, H2 2014 104
Colon Cancer - Pipeline by NewLink Genetics Corporation, H2 2014 105
Colon Cancer - Pipeline by Omeros Corporation, H2 2014 106
Colon Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2014 107
Colon Cancer - Pipeline by Oncology Research International Limited, H2 2014 108
Colon Cancer - Pipeline by Onconova Therapeutics, Inc., H2 2014 109
Colon Cancer - Pipeline by OncoVista Innovative Therapies, Inc., H2 2014 110
Colon Cancer - Pipeline by Oncozyme Pharma Inc., H2 2014 111
Colon Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 112
Colon Cancer - Pipeline by Orega Biotech SAS, H2 2014 113
Colon Cancer - Pipeline by OSE Pharma SA, H2 2014 114
Colon Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H2 2014 115
Colon Cancer - Pipeline by Panacela Labs, Inc., H2 2014 116
Colon Cancer - Pipeline by Patrys Limited, H2 2014 117
Colon Cancer - Pipeline by Pharminox Limited, H2 2014 118
Colon Cancer - Pipeline by Pique Therapeutics, H2 2014 119
Colon Cancer - Pipeline by Piramal Enterprises Limited, H2 2014 120
Colon Cancer - Pipeline by Plexxikon Inc., H2 2014 121
Colon Cancer - Pipeline by Priaxon AG, H2 2014 122
Colon Cancer - Pipeline by Provecs Medical GmbH, H2 2014 123
Colon Cancer - Pipeline by Qu Biologics Inc., H2 2014 124
Colon Cancer - Pipeline by Quantum Pharmaceuticals, H2 2014 125
Colon Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 126
Colon Cancer - Pipeline by Santaris Pharma A/S, H2 2014 127
Colon Cancer - Pipeline by Sareum Holdings plc, H2 2014 128
Colon Cancer - Pipeline by Starpharma Holdings Limited, H2 2014 129
Colon Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 130
Colon Cancer - Pipeline by Tautatis Incorporated, H2 2014 131
Colon Cancer - Pipeline by Telik, Inc., H2 2014 132
Colon Cancer - Pipeline by Transgene Biotek Limited, H2 2014 133
Colon Cancer - Pipeline by TransTech Pharma, Inc., H2 2014 134
Colon Cancer - Pipeline by TVAX Biomedical, Inc., H2 2014 135
Colon Cancer - Pipeline by Tyg Oncology Ltd, H2 2014 136
Colon Cancer - Pipeline by Vaccinogen, Inc., H2 2014 137
Colon Cancer - Pipeline by Viventia Biotechnologies Inc., H2 2014 138
Colon Cancer - Pipeline by Yakult Honsha Co., Ltd., H2 2014 139
Colon Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2014 140
Assessment by Monotherapy Products, H2 2014 141
Assessment by Combination Products, H2 2014 142
Number of Products by Stage and Target, H2 2014 144
Number of Products by Stage and Mechanism of Action, H2 2014 148
Number of Products by Stage and Route of Administration, H2 2014 152
Number of Products by Stage and Molecule Type, H2 2014 154
Colon Cancer Therapeutics - Recent Pipeline Updates, H2 2014 373
Colon Cancer - Dormant Projects, H2 2014 420
Colon Cancer - Discontinued Products, H2 2014 424